Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - INNOVUS PHARMACEUTICALS, INC. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): May 9,
2017
INNOVUS PHARMACEUTICALS,
INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-52991
|
90-0814124
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File
Number)
|
(IRS
Employer Identification No.)
|
|
9171 Towne Centre
Drive, Suite 440, San Diego, CA
|
|
92122
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (858) 964-5123
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR
240.13e-4(c))
|
In this
report, “Innovus Pharmaceuticals,” “Innovus
Pharma,” “the Company”, “we,”
“us” and “our” refer to Innovus
Pharmaceuticals, Inc., and/or one or more of our wholly-owned
subsidiaries, unless the context otherwise provides. Innovus
Pharma® is a registered service mark of Innovus
Pharmaceuticals, Inc.
Item 8.01 – Other Events
On May 9, 2017, the Company issued a press release announcing that
West-Ward Pharmaceuticals International Limited
(“WWPIL”), a wholly-owned subsidiary of Hikma
Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai:
HIK) (OTC: HKMPY), will provide the Company with the rights to
launch our branded, fluticasone propionate nasal spray USP, 50 mcg
per spray (FlutiCare™), under WWPIL’s FDA approved
abbreviated new drug application (“ANDA”) No. 207957 in
the United States in the second half of 2017.
This is
the second partnership the Company has announced for its
FlutiCare™ product. The first, originally announced in
connection with the Company’s acquisition of Novalere FP,
Inc. in 2015, is pending FDA approval of the ANDA in the U.S. As a
result of the acquisition, Innovus Pharma owns worldwide rights
outside of the U.S. to this dossier and filing and intends to
commercialize FlutiCare™ through the use of its rights to the
U.S. dossier for the product.
The
full text of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K.
Item 9.01 -- Financial Statements and Exhibits
(d) Exhibits
|
Exhibit Number
|
|
Description
|
|
99.1
|
|
Press
release issued May 9, 2017.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
Date: May 9, 2017
|
INNOVUS
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
By: /s/ Bassam
Damaj
Bassam
Damaj
President and Chief Executive
Officer
|
|
EXHIBIT
INDEX
|
Exhibit
Number
|
|
Description
|
|
99.1
|
|
Press release
issued May 9, 2017.
|